Company intelligence / Profile preview

Vitalex Biosciences

Irvine, California, United States

Ownership: Private
Employees: ~1
Development stage: Other

Overview

Vitalex is advancing a monoclonal antibody (VX-01) for mucormycosis and a dual-antigen vaccine (VXV-01) targeting invasive fungal infections and Gram-negative bacteria, both supported by significant NIH/NIAID funding. Main candidates have demonstrated efficacy in animal models; clinical trials have not yet started[5][1][2][6].

Therapeutic areas: Infectious Diseases
Modalities: Monoclonal antibodyVaccineDiagnostic
Industry: Biotech

Drug pipeline

1 asset

VX01

Preclinical

Partnerships

Appili Therapeutics (co-development of VXV-01)[2]The Lundquist Institute (incubator/academic collaboration)[5]JOINN Biologics (manufacturing/CDMO partner for VX-01)[5]BrevisRefero Corporation (CMC services for VX-01)[5]

Beyond the preview

Go deeper on Vitalex Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vitalex Biosciences.

Explore the full profile